Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression

American Journal of Hematology

Volumn 89, Issue 2, 2014, Pages 181-186

  Hou, Hsin An ^a   Kuo, Yuan Yeh ^a   Tang, Jih Luh ^a   Chou, Wen Chien ^a,b   Yao, Ming ^a   Lai, Yan Jun ^a   Lin, Chien Chin ^a   Chen, Chien Yuan ^a   Liu, Chieh Yu ^c   Tseng, Mei Hsuan ^a   Huang, Chi Fei ^a   Chiang, Ying Chieh ^a   Lee, Fen Yu ^b   Liu, Ming Chih ^b   Liu, Chia Wen ^b   Huang, Shang Yi ^a   Ko, Bor Sheng ^a   Wu, Shang Ju ^a   Tsay, Woei ^a   Chen, Yao Chang ^a,b   Tien, Hwei Fang ^a   more..

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; BINDING PROTEIN; SET BINDING PROTEIN 1; SRSF2 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME 17Q; CHROMOSOME ABERRATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE CLASSIFICATION; DISEASE COURSE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; ISOCHROMOSOME; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SEQUENTIAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CARRIER PROTEINS; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARYOTYPE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; YOUNG ADULT;

EID: 84893950322     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23611     Document Type: Article

References (32)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
2. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-1885.
3. Yunis JJ, Boot AJ, Mayer MG, et al. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene 1989;4:609-614.
4. Harada H, Harada Y, Niimi H, et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004;103:2316-2324.
5. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
6. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
7. Minakuchi M, Kakazu N, Gorrin-Rivas MJ, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem 2001;268:1340-1351.
8. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2012;45:18-24.
9. Hoischen A, van Bon BW, Gilissen C, et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet 2010;42:483-485.
10. Cristobal I, Blanco FJ, Garcia-Orti L, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010;115:615-625.
11. Schinzel A, Giedion A. A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs. Am J Med Genet 1978;1:361-375.
12. Verloes A, Moes D, Palumbo L, et al. Schinzel-Giedion syndrome. Eur J Pediatr 1993;152:421-423.
13. Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia (CMML): Independent prognostic impact in CMML. Leukemia 2013 [Epub ahead of print].
14. Damm F, Itzykson R, Kosmider O, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia 2013;27:1401-1403.
15. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: The age-dependent incidences and the stability during disease evolution. Cancer Res 2006;66:3310-3316.
16. Chen CY, Lin LI, Tang JL, et al. Acquisition of JAK2, PTPN11, and RAS mutations during disease progression in primary myelodysplastic syndrome. Leukemia 2006;20:1155-1158.
17. Hou HA, Chou WC, Lin LI, et al. Characterization of acute myeloid leukemia with PTPN11 mutation: The mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. Leukemia 2008;22:1075-1078.
18. Shiah HS, Kuo YY, Tang JL, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia 2002;16:196-202.
19. Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations. Blood 2009;114:5352-5361.
20. Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010;115:5222-5231.
21. Chou WC, Huang HH, Hou HA, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 2010;116:4086-4094.
22. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749-2754.
23. Chou WC, Lei WC, Ko BS, et al. The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011;25:246-253.
24. Chou WC, Chou SC, Liu CY, et al. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 2011;118:3803-3810.
25. Hou HA, Kuo YY, Liu CY, et al. DNMT3A mutations in acute myeloid leukemia: Stability during disease evolution and clinical implications. Blood 2012;119:559-568.
26. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
27. Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012;120:3106-3111.
28. Tien HF, Wang CH, Lin MT, et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia-A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995;84:60-68.
29. Chen CY, Lin LI, Tang JL, et al. RUNX1 gene mutation in primary myelodysplastic syndrome-The mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007;139:405-414.
30. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
31. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
32. Hideki Makishima KY, Nhu Nguyen, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013;45:942-946.